During a live event, Edward Pearson, MD, and participants discussed their approaches to using JAK inhibitors in myelofibrosis based on blood cell counts.
Symptomatic Patients With Myelofibrosis Treated Post-JAK Inhibition
During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.